# Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders

> **NCT07522255** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Mahidol University** · enrollment: 78 (estimated)

## Conditions studied

- Bloating
- Rifaximin
- Functional Bowel Disorder
- Irritable Bowel Syndrome
- Constipation

## Interventions

- **DRUG:** Rifaximin (drug)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07522255
- **Lead sponsor:** Mahidol University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-10
- **Final completion:** 2027-12
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07522255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07522255, "Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07522255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*